# Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

> **NCT06270316** · PHASE1,PHASE2 · RECRUITING · sponsor: **UniQure Biopharma B.V.** · enrollment: 12 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** AMT-191

## Key facts

- **NCT ID:** NCT06270316
- **Lead sponsor:** UniQure Biopharma B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2027-12-01
- **Final completion:** 2031-04-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270316, "Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06270316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*